{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:38Z","timestamp":1793210858310,"version":"4.5.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":264,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alemtuzumab is a powerful anti-CD52 drug that is an established treatment option in patients with multiple sclerosis due to its proven efficacy. However, in about 50% of patients, the use of alemtuzumab is burdened by the development of secondary autoimmune thyroid diseases, constituting a range of alemtuzumab-induced autoimmune thyroid diseases (AIATDs). Graves' disease (GD) is the most common AIATD, with an incidence of approximately 60%, and presents different characteristics from the conventional form. Indeed, GD with a fluctuating course is significantly more prevalent (15\u201350%), which poses a major challenge for physicians in its management. Other AIATDs also exhibit distinct features compared to their conventional counterparts; notably, hypothyroidism is frequently associated with TSH-receptor blocking antibodies, and alemtuzumab-induced GD demonstrates a higher rate of fluctuating course and potential for spontaneous remission. Alemtuzumab-induced thyroid eye disease (TED) is less common than conventional TED, with similar clinical and management characteristics. In this review, we summarize the latest evidence, also from real-world studies, with a focus on clinical management and possible predictors of AIATDs.<\/jats:p>","DOI":"10.1530\/etj-25-0007","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:47:12Z","timestamp":1748526432000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":8,"title":["Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-4339","authenticated-orcid":true,"given":"Jacopo","family":"Manso","sequence":"first","affiliation":[{"name":"Endocrinology Unit, University Hospital S. Maria della Misericordia of Udine, Oncology Area Deparment, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2926-0722","authenticated-orcid":true,"given":"Ilaria","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan 2 , ,","place":["Milan, Italy"]},{"name":"Graves' Orbitopathy Center, Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico 3 , ,","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8001","authenticated-orcid":true,"given":"Caterina","family":"Mian","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Medicine (DIMED), University of Padua 4 , ,","place":["Padua, Italy"]},{"name":"Endocrine Unit, University Hospital of Padua 5 , ,","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2026070712522678300_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000339757","article-title":"The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data","volume":"39","author":"Marrie","year":"2012","journal-title":"Neuroepidemiology"},{"key":"2026070712522678300_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"key":"2026070712522678300_bib3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"2026070712522678300_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1385\/MO:19:2S:S03","article-title":"A personal history of the CAMPATH-1H antibody","volume":"19","author":"Waldmann","year":"2002","journal-title":"Med Oncol"},{"key":"2026070712522678300_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026070712522678300_bib6","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712522678300_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"2026070712522678300_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000500881","article-title":"2019 European Thyroid Association Guidelines on the management of thyroid dysfunction following immune reconstitution therapy","volume":"8","author":"Muller","year":"2019","journal-title":"Eur Thyroid J"},{"key":"2026070712522678300_bib9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.1780381110","article-title":"Campath-1h, a humanized monoclonal antibody, in refractory rheumatoid arthritis","volume":"38","author":"Weinblatt","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2026070712522678300_bib10","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"2007","journal-title":"Oncogene"},{"key":"2026070712522678300_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/art.23122","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes","volume":"58","author":"Lorenzi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026070712522678300_bib12","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Investig"},{"key":"2026070712522678300_bib13","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070712522678300_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712522678300_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.82.10_supplement.P2.199","article-title":"Thyroid autoimmune adverse events in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: four-year follow-up of the CARE-MS studies (P2.199)","volume":"82","author":"Twyman","year":"2014","journal-title":"Neurology"},{"key":"2026070712522678300_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Scappaticcio","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"2026070712522678300_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.14616","article-title":"Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: a real-life and monocentric experience at a tertiary-level centre","volume":"97","author":"Manso","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026070712522678300_bib18","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1089\/thy.2018.0232","article-title":"Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that TRAb may precede thyroid dysfunction by many years","volume":"28","author":"Muller","year":"2018","journal-title":"Thyroid"},{"key":"2026070712522678300_bib19","article-title":"Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies","volume":"9","author":"Dayan","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2026070712522678300_bib20","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s10238-022-00981-3","article-title":"Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study","volume":"23","author":"Kazakou","year":"2023","journal-title":"Clin Exp Med"},{"key":"2026070712522678300_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105880","article-title":"Alemtuzumab-induced thyroid disease: a Danish cohort study","volume":"91","author":"Hansen","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026070712522678300_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/clinem\/dgad540","article-title":"Prevalence, risk factors, and clinical and biochemical characteristics of alemtuzumab-induced graves disease","volume":"109","author":"Ueland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712522678300_bib23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"2026070712522678300_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ebiom.2019.07.062","article-title":"Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: a prospective cohort study","volume":"46","author":"Ruck","year":"2019","journal-title":"EBioMedicine"},{"key":"2026070712522678300_bib25","article-title":"Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset","volume":"6","author":"Yap","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2026070712522678300_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2013-307042","article-title":"Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis","volume":"85","author":"Azzopardi","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026070712522678300_bib27","first-page":"168","article-title":"Management of Graves' ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"2026070712522678300_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026070712522678300_bib29","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"2026070712522678300_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026070712522678300_bib31","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712522678300_bib32","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712522678300_bib33","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026070712522678300_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series","volume":"33","author":"Roos","year":"2019","journal-title":"Eye"},{"key":"2026070712522678300_bib35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00415-023-11995-6","article-title":"Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis","volume":"271","author":"Rodriguez de Vera Gomez","year":"2024","journal-title":"J Neurol"},{"key":"2026070712522678300_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/IOP.0000000000002367","article-title":"Alemtuzumab-induced thyroid eye disease: a comprehensive case series and review of the literature","volume":"39","author":"Nirmalan","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2026070712522678300_bib37","article-title":"Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab","volume":"13","author":"Muller","year":"2024","journal-title":"Eur Thyroid J"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/3\/ETJ-25-0007.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/3\/ETJ-25-0007.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0007\/32446\/etj-25-0007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0007\/32446\/etj-25-0007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:21:34Z","timestamp":1783444894000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/3\/e250007\/4352\/Clinical-management-of-alemtuzumab-induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0007","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"e250007"}}